Slide 1: BioSyent Inc. Q1 2024 Results
BioSyent BioSyentInc. Inc. Q4 Q1 / FY2024 2023Results Results MARCH 13, 2024 2024 MAY 16, PRESENTED BY: RENÉ GOEHRUM PRESENTED BY: RENÉ GOEHRUM PRESIDENT AND CEO PRESIDENT AND CEO 1 | www.biosyent.com | TSXV: RX 1 | www.biosyent.com | TSXV: RX
Slide 2: Disclaimer
DISCLAIMER This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements
Slide 3: 3 | www.biosyent.com | TSXV: RX | www.biosyent.com | TSXV: RX
3 | www.biosyent.com | TSXV: RX 3 | www.biosyent.com | TSXV: RX
Slide 4: Q1 2024 Sales Summary ($)
Q1 2024 Sales Summary ($) Q1 ’24 Q1 ‘24 vs. TTM Mar 31‘24 TTM Mar 31’24 vs. Sales ($) Q1 ’23 (%) Sales ($) TTM Mar 31’23 (%) Canadian Pharma ($) $7,546k +18% $30,689k +16% FeraMAX® Pd +16% +16% RepaGyn® +26% +12% Tibella® +31% +44% Combogesic® +126% (37%) Inofolic® n/a n/a Cathejell® +1% +4% Gelclai
Slide 5: Sales, EBITDA and NIAT
Sales, EBITDA and NIAT Quarter (Q1) ended March 31st 9,000 Sales +18% Canadian Pharma 8,000 +19% +35% - International Pharma 7,000 +164% Legacy -8% 6,000 EBITDA / NIAT • EBITDA Margin Q1 2024: 29% to Sales CAD (000's) 5,000 4,000 Q1 2023: 23% to Sales 3,000 • NIAT Margin +45% Q1 2024: 23% to Sales 2
Slide 6: Fully Diluted Earnings per Share
Fully Diluted Earnings per Share Quarter NIAT Diluted EPS 55 Consecutive Profitable Quarters Q1 2024 $1,768,727 $0.15 to Q1 2024 Q4 2023 $1,450,791 $0.12 $0.59 TTM Q3 2023 $2,350,900 $0.20 Q2 2023 $1,483,190 $0.12 Q1 2023 $1,175,246 $0.10 Q4 2022 $1,199,516 $0.09 $0.41 TTM Q3 2022 $1,453,042 $0.12 Q
Slide 7: 2024 YTD Highlights
2024 YTD Highlights ▪ Feb 2024: Increased quarterly dividend of $0.045 declared (+12.5% increase) ▪ Feb 2024: BioSyent named to 2024 TSX Venture 50 ▪ Apr 2024: FeraMAX® named #1 recommended iron supplement in Canada for ninth consecutive year ▪ Apr 2024: Extension of RepaGyn® and Proktis-M® Agreemen
Slide 8: Most recommended iron supplement in Canada
9 ▪ Most recommended iron supplement in Canada - pharmacists and physicians - 9 consecutive years(1) ▪ Continued innovation and expansion of FeraMAX® product line for iron health (1) Based on Pharmacy Practice + Business, The Medical Post and Profession Santé 2024 Survey on OTC Counselling and Recom
Slide 9: FeraMAX LifeCycle Strategy: Iron health for life
FeraMAX® LifeCycle Strategy ▪ Expanding leadership of FeraMAX® brand in Canada: “Iron health for life” ▪ FeraMAX® Pd platform introduced in October 2020 ▪ Patented delivery system based on Polydextrose Iron Complex (PDIC) ▪ FeraMAX® Pd Therapeutic 150 launched Nov 2020 ▪ FeraMAX® Pd Powder 15 launch
Slide 10: NEW in 2023 - FeraMAX Pd Maintenance 45
NEW in 2023 - FeraMAX® Pd Maintenance 45 ▪ Developed by BioSyent ▪ 3rd product incorporating PDIC ▪ Designed to: ▪ prevent iron deficiency ▪ maintain healthy iron levels ▪ Unique formulation: ▪ chewable ▪ pleasant taste ▪ 45 mg elemental iron ▪ supportive vitamins for iron health ▪ Launched in Canad
Slide 11: NEW in 2023 - Inofolic
NEW in 2023 - Inofolic® ▪ Launched in Canada in August 2023 ▪ New treatment option for women with Polycystic Ovary Syndrome (PCOS), an endocrine disorder, to help manage: ▪ Insulin resistance ▪ Infertility ▪ Menstrual dysfunction ▪ Skin manifestations ▪ Hirsutism (Excess hair growth) ▪ Alopecia (Hai
Slide 12: NEW in 2023 - Gelclair
NEW in 2023 - Gelclair® ▪ Oncology supportive care product for relief of oral mucositis ▪ Frequently experienced by cancer patients undergoing radiation or chemotherapy ▪ Protective concentrated gel which adheres to the mucosa of the mouth, providing: ▪ Fast pain relief ▪ Improved ability to eat, dr
Slide 13: Innovations and Product Launches
Innovations and Product Launches Tibella® Jul 2020 FeraMAX® Pd Oct 2020 FeraMAX® Pd Therapeutic 150 Nov 2020 Combogesic® Dec 2020 FeraMAX® Pd Powder 15 Oct 2021 FeraMAX® Pd Maintenance 45 Mar 2023 Inofolic® Aug 2023 Gelclair® Nov 2023 13 | www.biosyent.com | TSXV: RX
Slide 14: Growth Drivers
Growth Drivers Management of symptoms of PCOS Oncology supportive care product for Oral Mucositis FeraMAX® Pd Platform – Life Cycle Strategy In development HRT agent for menopause therapy Acquisition and in-licensing – ongoing 14 | www.biosyent.com | TSXV: RX
Slide 15: Cash Balance & Return on Equity
Cash Balance & Return on Equity (“RoE”) • Zero Debt 30,000 25% • TTM Mar 31’24 Cash from 27,794 21% 25,000 26,844 21% 26,249 Operations of $7.1M 20% 15% • Highest ever TTM cash 20,000 from operations 15% • TTM Mar 31’24 NCIB share 15,000 buybacks: $4.0 M CAD (000's) RoE % 10% • 503,500 shares 10,000
Slide 16: Capital Allocation linked to Strategy
Capital Allocation linked to Strategy First use of capital is to generate revenue growth & portfolio diversification Cash: Dividends $27.8M Growth & Diversification Debt: Share $0M Buybacks Excess capital may also be returned to shareholders: • Quarterly Dividends – Q4’22 – Q2’24 = $ 3.4 M to date (
Slide 17: Stock Information
Stock Information As at May 14, 2024 Exchange & Trading Symbol 0% TSXV: RX May 14, 2024 Closing Stock Price (CAD) (TSXV): $8.37 52 Week Hi/Low (TSXV): $9.26 / $7.03 Issued Common Shares: 11,785,641 Treasury – RSU Shares in Trust (200,472) RSUs funded Outstanding Common Shares: 11,585,169 with shares
Slide 18: Profitable. Well Capitalized. Growth Assets.
PROFITABLE. WELL CAPITALIZED. GROWTH ASSETS. FOCUSED ON LONG-TERM GROWTH AND TOTAL SHAREHOLDER RETURN. 18 www.biosyent.com | TSXV: RX